(Q26748018)

title

Challenges and strategies in anti-cancer nanomedicine development: An industry perspective (English)

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137110%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Jennifer I Hare

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137110%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Marianne B Ashford

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137110%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Sanyogitta Puri

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137110%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Gert Storm

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137110%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Simon T Barry

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137110%20AND%20SRC:MED&resulttype=core&format=json

Advanced Drug Delivery Reviews

5 June 2020

language of work or name

English

0 references

publication date

29 April 2016

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137110%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137110%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

25-38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27137110%20AND%20SRC:MED&resulttype=core&format=json

Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research

5 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

A nanoparticle size series for in vivo fluorescence imaging

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

A pharmacokinetic model for quantifying the effect of vascular permeability on the choice of drug carrier: a framework for personalized nanomedicine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

A novel method for imaging in vivo degradation of poly(L-glutamic acid), a biodegradable drug carrier.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Microvascular permeability of normal and neoplastic tissues

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Polymer therapeutics-prospects for 21st century: the end of the beginning

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Cancer nanomedicines: so many papers and so few drugs!

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Polymer-drug conjugates: origins, progress to date and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Dynamic imaging of PEGylated indocyanine green (ICG) liposomes within the tumor microenvironment using multi-spectral optoacoustic tomography (MSOT).

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Preclinical mouse cancer models: a maze of opportunities and challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Overcoming the stromal barrier for targeted delivery of HPMA copolymers to pancreatic tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Doxil®--the first FDA-approved nano-drug: lessons learned

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release II: impact of release rate on biodistribution

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Tumor perfusion imaging predicts the intra-tumoral accumulation of liposomes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

A novel approach for the intravenous delivery of leuprolide using core-cross-linked polymeric micelles.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Spatial and temporal mapping of heterogeneity in liposome uptake and microvascular distribution in an orthotopic tumor xenograft model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

The intra-tumoral relationship between microcirculation, interstitial fluid pressure and liposome accumulation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

The big picture on nanomedicine: the state of investigational and approved nanomedicine products

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Just so stories: the random acts of anti-cancer nanomedicine performance

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Tumour stromal morphology impacts nanomedicine cytotoxicity in patient-derived xenografts.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Odyssey of a cancer nanoparticle: from injection site to site of action

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Nanotheranostics and image-guided drug delivery: current concepts and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Nanomedicine(s) under the microscope

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Facing the truth about nanotechnology in drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Pathology: cancer cells compress intratumour vessels.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Human tumor xenografts: the good, the bad, and the ugly

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Molecular mechanisms and clinical applications of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Principles of nanoparticle design for overcoming biological barriers to drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Tumour-on-a-chip provides an optical window into nanoparticle tissue transport.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Translational value of mouse models in oncology drug development

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Strategies for advancing cancer nanomedicine

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Seven challenges for nanomedicine

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Delivering nanomedicine to solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Why are tumour blood vessels abnormal and why is it important to know?

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Size-dependent biodistribution and antitumor efficacy of polymer micelle drug delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Hydrogel drug delivery system with predictable and tunable drug release and degradation rates

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Cancer nanomedicine: from drug delivery to imaging

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Nanoparticles for imaging: top or flop?

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammography.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Normalization of the vasculature for treatment of cancer and other diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Personalized nanomedicine

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302).

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Combined analysis of phase III trials evaluating [⁹⁹mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Image-guided drug delivery: preclinical applications and clinical translation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021

Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FJ.ADDR.2016.04.025

7 January 2021